for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

65.74USD

Change

0.00(0.00%)

Volume

2,485

Today's Range

--

 - 

--

52 Week Range

15.52

 - 

95.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
65.74
Open
0.00
Volume
2,485
3M AVG Volume
220.50
Today's High
--
Today's Low
--
52 Week High
95.21
52 Week Low
15.52
Shares Out (MIL)
394.59
Market Cap (MIL)
27,885.45
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Moderna Inc Earnings Call

Latest Developments

More

Moderna Says Initiation Of Rolling Submission To Health Canada For MRNA-1273, Co's Covid-19 Vaccine Candidate

Statement By Moderna On Intellectual Property Matters During The Covid-19 Pandemic

Moderna Vows To Not Enforce Covid-19 Vaccine Patents During Pandemic - WSJ

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Key Stats

2.07 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020(E)

0.3K
EPS (USD)

2018

-4.950

2019

-1.550

2020(E)

-1.459
Price To Earnings (TTM)
--
Price To Sales (TTM)
263.47
Price To Book (MRQ)
9.43
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.31
LT Debt To Equity (MRQ)
2.31
Return on Investment (TTM)
-20.10
Return on Equity (TTM)
-18.84

Latest News

Latest News

Japan's Takeda to import 50 million doses of Moderna's COVID-19 vaccine, raises profit forecast

Japan's Takeda Pharmaceutical Co said on Thursday it would import and distribute 50 million doses of Moderna Inc's novel coronavirus vaccine candidate.

UK starts real-time review of Moderna's COVID-19 vaccine candidate

Moderna Inc said on Tuesday United Kingdom's health regulator has started a real-time review of its experimental COVID-19 vaccine.

UK starts real-time review of Moderna's COVID-19 vaccine candidate

Moderna Inc said on Tuesday United Kingdom's health regulator has started a real-time review of its experimental COVID-19 vaccine candidate.

Qatar signs deal to buy Moderna COVID-19 vaccine

Qatar has signed an agreement with drugmaker Moderna Inc <MRNA.O> to buy its potential COVID-19 vaccine as soon as it is approved and released for global use, state news agency QNA quoted a health official as saying on Sunday.

Moderna completes enrollment in large COVID-19 vaccine study

Moderna Inc said on Thursday it had completed the enrollment of 30,000 participants in a late-stage study testing its experimental coronavirus vaccine, with over a third of the participants from communities of color.

Moderna completes enrollment in its large COVID-19 vaccine study

Moderna Inc said on Thursday it has completed enrolling 30,000 participants in a late-stage study testing its experimental coronavirus vaccine.

U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end - official

The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.

UPDATE 1-Spain's Rovi plans to start manufacturing Moderna vaccine 'very soon'

Spain's pharmaceutical firm Rovi , in charge of the "fill and finish" final stage of manufacturing for Moderna's COVID-19 vaccine candidate outside the United States, said on Tuesday it expects to start work on the vaccine "very soon" if it is approved by regulators.

Spain's Rovi to start manufacturing Moderna vaccine "very soon" if approved

Spain's pharmaceutical firm Rovi, in charge of the "fill and finish" final stage of manufacturing for Moderna's COVID-19 vaccine candidate outside the United States, said on Tuesday it expects to start producing the vaccine "very soon" if it is approved by regulators.

Moderna CEO expects COVID-19 vaccine interim results in November: WSJ

Moderna Inc Chief Executive Officer Stéphane Bancel expects interim results from its COVID-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported https://www.wsj.com/articles/moderna-ceo-expects-covid...

Canada to review Moderna's COVID-19 vaccine candidate in real time

Moderna Inc said on Tuesday Canada's health ministry will review its experimental COVID-19 vaccine in real time, becoming the third vaccine maker to be accepted by the country for the process that may speed up approval.

WHO welcomes Moderna move not to enforce COVID-19 vaccine patents

World Health Organization chief Tedros Adhanom Ghebreyesus welcomed on Friday U.S. drug company Moderna Inc's decision not to enforce patents related to its experimental COVID-19 vaccine while the pandemic continues.

Moderna to apply for EU's rolling approval for COVID-19 vaccine

Moderna Inc will soon apply for real-time reviews of its experimental COVID-19 vaccine in Europe, the drug developer said on Thursday, days after the EU health regulator launched rolling reviews of shots from its rivals.

Moderna will not enforce COVID-19 vaccine patents during pandemic

Moderna Inc said on Thursday it would not enforce patents related to its experimental COVID-19 vaccine while the pandemic continues, a move that would allow other drugmakers to develop shots using the company's technology.

U.S. vaccine program head Slaoui expects Pfizer, Moderna vaccine data readouts in November-December

The chief adviser for the U.S. government's Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, on Tuesday said efficacy data readouts are expected from Pfizer Inc and Moderna Inc between next month and December.

Exclusive: Moderna vaccine trial contractors fail to enroll enough minorities, prompting slowdown

Private contractors hired by Moderna Inc to recruit volunteers for its coronavirus vaccine trial failed to enroll enough Black, Latino and Native American participants to determine how well the vaccine works in these populations, company executives and vaccine researchers...

Exclusive: Moderna vaccine trial contractors fail to enroll enough minorities, prompting slowdown - sources

Private contractors hired by Moderna Inc to recruit volunteers for its coronavirus vaccine trial failed to enroll enough Black, Latino and Native American participants to determine how well the vaccine works in these populations, company executives and vaccine researchers...

Moderna says COVID-19 vaccine unlikely to be ready before U.S. election - FT

Moderna Inc will not be ready to apply for emergency authorization for its potential COVID-19 vaccine before the U.S. presidential election in November, the Financial Times reported on Wednesday, citing the company's chief executive officer.

Moderna says seeking approval for COVID-19 vaccine not possible before U.S. elections - FT

Moderna Inc said on Wednesday it will not be ready to apply for emergency approval for its potential COVID-19 vaccine before the U.S. presidential elections in November, the Financial Times reported.

Moderna COVID-19 vaccine appears safe, shows signs of working in older adults: study

Results from an early safety study of Moderna Inc's <MRNA.O> coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots,...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up